Multicenter Study of 9-Aminocamptothecin (9-AC) in Patients With Refractory Leukemia
Primary Purpose
Leukemia, Myelocytic, Acute, Acute Lymphocytic Leukemia
Status
Completed
Phase
Phase 1
Locations
United States
Study Type
Interventional
Intervention
9-Aminocamptothecin (9-AC)
Sponsored by
About this trial
This is an interventional treatment trial for Leukemia, Myelocytic, Acute focused on measuring leukemia, 9-Aminocamptothecin, AML, ALL, refractory leukemia, relapsed leukemia
Eligibility Criteria
Inclusion Criteria: 18 years of age or older AML or ALL in first or subsequent relapse, secondary AML, or CML in blastic phase Central venous access ECOG performance status of less than or equal to 2 Bilirubin < 1.3 SGOT < 2 x ULN Alkaline phosphatase < 2 x ULN Creatinine < 1.5 Exclusion Criteria: Undergone bone marrow transplantation Uncontrolled infection Other active malignancy HIV positivity Serious medical or psychiatric illness Pregnancy
Sites / Locations
- Massachusetts General Hosptial
- Dana-Farber Cancer Institute
Outcomes
Primary Outcome Measures
To evaluate the toxicity and maximum tolerated dose of 9-AC administered as a 72 hour infusion in patients with relapsed/refractory leukemia.
Secondary Outcome Measures
To analyze the pharmacokinetics in these patients.
Full Information
NCT ID
NCT00251368
First Posted
November 8, 2005
Last Updated
March 9, 2011
Sponsor
Dana-Farber Cancer Institute
Collaborators
Brigham and Women's Hospital, Beth Israel Deaconess Medical Center, Massachusetts General Hospital
1. Study Identification
Unique Protocol Identification Number
NCT00251368
Brief Title
Multicenter Study of 9-Aminocamptothecin (9-AC) in Patients With Refractory Leukemia
Official Title
Multicenter Study of 9-AC in Refractory Leukemia
Study Type
Interventional
2. Study Status
Record Verification Date
March 2011
Overall Recruitment Status
Completed
Study Start Date
January 1995 (undefined)
Primary Completion Date
September 2007 (Actual)
Study Completion Date
September 2007 (Actual)
3. Sponsor/Collaborators
Name of the Sponsor
Dana-Farber Cancer Institute
Collaborators
Brigham and Women's Hospital, Beth Israel Deaconess Medical Center, Massachusetts General Hospital
4. Oversight
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
The purpose of this study is to evaluate the side effects of 9-Aminocamptothecin (9-AC) and to determine the best dose which should be used to treat leukemia.
Detailed Description
The treatment patients will receive involves a continuous infusion of 9-AC intravenously for a 72 hour period. Since we are unsure of the safest and most effective dose, successive groups of 4-7 patients will receive larger doses of this drug until the largest dose given safely is established.
Prior to the start of therapy a bone marrow aspirate and biopsy will be taken for diagnostic and research purposes. A bone marrow exam will be repeated at 48 hours in order to determine the effects of 9-AC on leukemic cells in the bone marrow. A bone marrow scan will also be performed 14 days after the start of therapy to assess response.
Frequent blood testing will be done throughout treatment, including blood samples to determine the levels of the 9-AC in the blood.
Treatment could be stopped prematurely if any of the following occur: 1) drug causes severe side effects, 2) the drug does not control the leukemia, or 3) the doctors or the patient feel that it is no longer in the patients best interest to receive this therapy.
Approximately 7 days after the conclusion of the 9-AC infusion, it is likely that the patient's blood counts will be low and will require support with antibiotics, red cell transfusions and platelet transfusions.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Leukemia, Myelocytic, Acute, Acute Lymphocytic Leukemia
Keywords
leukemia, 9-Aminocamptothecin, AML, ALL, refractory leukemia, relapsed leukemia
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 1
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
Non-Randomized
Enrollment
52 (Anticipated)
8. Arms, Groups, and Interventions
Intervention Type
Drug
Intervention Name(s)
9-Aminocamptothecin (9-AC)
Primary Outcome Measure Information:
Title
To evaluate the toxicity and maximum tolerated dose of 9-AC administered as a 72 hour infusion in patients with relapsed/refractory leukemia.
Time Frame
Years
Secondary Outcome Measure Information:
Title
To analyze the pharmacokinetics in these patients.
Time Frame
years
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
18 years of age or older
AML or ALL in first or subsequent relapse, secondary AML, or CML in blastic phase
Central venous access
ECOG performance status of less than or equal to 2
Bilirubin < 1.3
SGOT < 2 x ULN
Alkaline phosphatase < 2 x ULN
Creatinine < 1.5
Exclusion Criteria:
Undergone bone marrow transplantation
Uncontrolled infection
Other active malignancy
HIV positivity
Serious medical or psychiatric illness
Pregnancy
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Richard Stone, MD
Organizational Affiliation
Dana-Farber Cancer Institute
Official's Role
Principal Investigator
Facility Information:
Facility Name
Massachusetts General Hosptial
City
Boston
State/Province
Massachusetts
ZIP/Postal Code
02114
Country
United States
Facility Name
Dana-Farber Cancer Institute
City
Boston
State/Province
Massachusetts
ZIP/Postal Code
02115
Country
United States
12. IPD Sharing Statement
Learn more about this trial
Multicenter Study of 9-Aminocamptothecin (9-AC) in Patients With Refractory Leukemia
We'll reach out to this number within 24 hrs